Posted by Michael Wonder on 11 Jul 2023
Xspray Pharma receives request for additional information concerning Dasynoc from FDA
11 July 2023 - Xspray Pharma announces an update on recent developments regarding the company’s first product, Dasynoc, currently under review by the US FDA.
The company has received a complete response letter whereby the FDA request additional information particularly regarding additional information to doctors and users related to Dasynoc dosing and a third-party manufacturing facility.
